Cargando…

Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD

Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunn, Keith, Baugh, Bryan, Bejou, Nika, Luo, Donghan, Campbell, Jennifer, Seyedkazemi, Sareh, Anderson, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044782/
https://www.ncbi.nlm.nih.gov/pubmed/35466761
http://dx.doi.org/10.1177/23259582221088202
_version_ 1784695178400890880
author Dunn, Keith
Baugh, Bryan
Bejou, Nika
Luo, Donghan
Campbell, Jennifer
Seyedkazemi, Sareh
Anderson, David
author_facet Dunn, Keith
Baugh, Bryan
Bejou, Nika
Luo, Donghan
Campbell, Jennifer
Seyedkazemi, Sareh
Anderson, David
author_sort Dunn, Keith
collection PubMed
description Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER (treatment-naïve) and EMERALD (virologically suppressed) studies of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg. 362 and 763 patients initiated D/C/F/TAF in AMBER and EMERALD, respectively. All D/C/F/TAF-related gastrointestinal AEOIs were grade 1/2 in severity; none were serious. Across studies, incidence of D/C/F/TAF-related diarrhea and nausea were each ≤5% in Wk1 (≤1% post-Wk2); prevalence of each decreased to <5% post-Wk2. In each study, there was 1 case of D/C/F/TAF-related abdominal discomfort during Wk1 and none thereafter. Incidence of D/C/F/TAF-related flatulence was <1% throughout. Median duration of D/C/F/TAF-related gastrointestinal AEOIs was 16.5 (AMBER) and 8.5 (EMERALD) days. In conclusion, in treatment-naïve and virologically suppressed patients, incidences and prevalences of D/C/F/TAF-related gastrointestinal AEOIs were low and tended to present early.
format Online
Article
Text
id pubmed-9044782
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-90447822022-04-28 Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD Dunn, Keith Baugh, Bryan Bejou, Nika Luo, Donghan Campbell, Jennifer Seyedkazemi, Sareh Anderson, David J Int Assoc Provid AIDS Care Original Research Article Gastrointestinal intolerance has been associated with ritonavir-boosted protease inhibitors. This post hoc analysis evaluated gastrointestinal adverse events of interest (AEOIs; diarrhea, nausea, abdominal discomfort, flatulence [MedDRAv21]) through Wk96 among patients enrolled in the phase 3 AMBER (treatment-naïve) and EMERALD (virologically suppressed) studies of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg. 362 and 763 patients initiated D/C/F/TAF in AMBER and EMERALD, respectively. All D/C/F/TAF-related gastrointestinal AEOIs were grade 1/2 in severity; none were serious. Across studies, incidence of D/C/F/TAF-related diarrhea and nausea were each ≤5% in Wk1 (≤1% post-Wk2); prevalence of each decreased to <5% post-Wk2. In each study, there was 1 case of D/C/F/TAF-related abdominal discomfort during Wk1 and none thereafter. Incidence of D/C/F/TAF-related flatulence was <1% throughout. Median duration of D/C/F/TAF-related gastrointestinal AEOIs was 16.5 (AMBER) and 8.5 (EMERALD) days. In conclusion, in treatment-naïve and virologically suppressed patients, incidences and prevalences of D/C/F/TAF-related gastrointestinal AEOIs were low and tended to present early. SAGE Publications 2022-04-24 /pmc/articles/PMC9044782/ /pubmed/35466761 http://dx.doi.org/10.1177/23259582221088202 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Dunn, Keith
Baugh, Bryan
Bejou, Nika
Luo, Donghan
Campbell, Jennifer
Seyedkazemi, Sareh
Anderson, David
Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
title Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
title_full Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
title_fullStr Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
title_full_unstemmed Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
title_short Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD
title_sort low incidence and brief duration of gastrointestinal adverse events with darunavir/cobicistat/emtricitabine/tenofovir alafenamide (d/c/f/taf) over 96 weeks: post hoc analyses of amber and emerald
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044782/
https://www.ncbi.nlm.nih.gov/pubmed/35466761
http://dx.doi.org/10.1177/23259582221088202
work_keys_str_mv AT dunnkeith lowincidenceandbriefdurationofgastrointestinaladverseeventswithdarunavircobicistatemtricitabinetenofoviralafenamidedcftafover96weeksposthocanalysesofamberandemerald
AT baughbryan lowincidenceandbriefdurationofgastrointestinaladverseeventswithdarunavircobicistatemtricitabinetenofoviralafenamidedcftafover96weeksposthocanalysesofamberandemerald
AT bejounika lowincidenceandbriefdurationofgastrointestinaladverseeventswithdarunavircobicistatemtricitabinetenofoviralafenamidedcftafover96weeksposthocanalysesofamberandemerald
AT luodonghan lowincidenceandbriefdurationofgastrointestinaladverseeventswithdarunavircobicistatemtricitabinetenofoviralafenamidedcftafover96weeksposthocanalysesofamberandemerald
AT campbelljennifer lowincidenceandbriefdurationofgastrointestinaladverseeventswithdarunavircobicistatemtricitabinetenofoviralafenamidedcftafover96weeksposthocanalysesofamberandemerald
AT seyedkazemisareh lowincidenceandbriefdurationofgastrointestinaladverseeventswithdarunavircobicistatemtricitabinetenofoviralafenamidedcftafover96weeksposthocanalysesofamberandemerald
AT andersondavid lowincidenceandbriefdurationofgastrointestinaladverseeventswithdarunavircobicistatemtricitabinetenofoviralafenamidedcftafover96weeksposthocanalysesofamberandemerald